Teva files IND for new MS treatment

Teva and Switzerland's Active Biotech have filed an IND for laquinimod for relapsing forms of multiple sclerosis. Laquinimod is a novel orally administered immunomodulatory substance developed by Active Biotech and recently licensed to Teva. A Phase III trial of the drug is scheduled to get started in 2006. "I am pleased to report on this significant milestone," said Israel Makov, president and CEO of Teva. "This IND filing is an important step towards the initiation of pivotal studies with laquinimod which, along with Teva's development of an oral form of Copaxone, enhance the likelihood that Teva will be the first to market an oral treatment."

- read this press release for more

ALSO: The FDA has granted Teva tentative approval for its generic version of Aventis' Amaryl tablets for diabetes. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.